| 000 | 01896 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513091457.0 | ||
| 264 | 0 | _c19960801 | |
| 008 | 199608s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 024 | 7 |
_a10.1016/0959-8049(95)00477-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGaraci, E | |
| 245 | 0 | 0 |
_aSequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cDec 1995 |
||
| 300 |
_a2403-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xtherapy |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aLung Neoplasms _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aThymalfasin |
| 650 | 0 | 4 |
_aThymosin _xadministration & dosage |
| 700 | 1 | _aLopez, M | |
| 700 | 1 | _aBonsignore, G | |
| 700 | 1 | _aDella Giulia, M | |
| 700 | 1 | _aD'Aprile, M | |
| 700 | 1 | _aFavalli, C | |
| 700 | 1 | _aRasi, G | |
| 700 | 1 | _aSantini, S | |
| 700 | 1 | _aCapomolla, E | |
| 700 | 1 | _aVici, P | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 31A _gno. 13-14 _gp. 2403-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0959-8049(95)00477-7 _zAvailable from publisher's website |
| 999 |
_c8651312 _d8651312 |
||